Regadenoson: a new myocardial stress agent.
Vasodilator stress myocardial perfusion imaging (MPI) accounts for up to 50% of all stress MPI studies performed in the U.S. In 2008, the Food and Drug Administration approved regadenoson for stress testing in conjunction with MPI. Regadenoson, unlike adenosine, is a selective A(2A) agonist that is given as an intravenous bolus at a fixed dose, with less undesirable side effects including atrioventricular block and bronchospasm. Unlike adenosine, regadenoson could be used in patients with mild-to-moderate reactive airway disease. This review will summarize the pre-clinical and clinical data on regadenoson, as they specifically relate to its use as a vasodilator stress agent, currently the only approved selective A(2A) agonist.
Al Jaroudi
Wael
W
Department of Medicine, The University of Alabama at Birmingham, USA. waljaroudi@cardmail.dom.uab.edu
Iskandrian
Ami E
AE
D001794:Blood Pressure / Q000187:drug effects; D003324:Coronary Artery Disease / Q000175:diagnosis* / Q000503:physiopathology; D005080:Exercise Test; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D055414:Myocardial Perfusion Imaging; D011687:Purines / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology*; D011720:Pyrazoles / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology*; D014665:Vasodilator Agents / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology*
D011687:Purines; D011720:Pyrazoles; D014665:Vasodilator Agents; C430916:regadenoson